Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.


Novel therapeutic strategy for Wilson disease

Wilson disease is characterized by exessive copper accumulation in the liver and fulminant hepatitis. A recent study has investigated the therapeutic potential of menthanobactin, a peptide produced by Methylosinus trichosporium OB3b that has a high affinity for copper. In a rat model of Wilson disease, short-term treatment with methanobactin was able to prevent hepatocyte death, subsequent liver failure and death. The researchers propose methanobactin as “the lead drug of choice to develop a more efficient and safe treatment of [Wilson disease]”.


  1. 1

    Lichtmannegger, J. et al. Methanobactin reverses acute liver failure in a rat model of Wilson disease. J. Clin. Invest.

Download references


Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Leake, I. Novel therapeutic strategy for Wilson disease. Nat Rev Gastroenterol Hepatol 13, 436 (2016).

Download citation


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing